Changes in glaucoma medication numbers after cataract and glaucoma surgery
A nationwide population-based study

Hsin-Yi Chen, MDa,b,∗, Cheng-Li Lin, MScac, Chia-Hung Kao, MDd,e,f,*

Abstract
To determine whether cataract or glaucoma and combined cataract and glaucoma surgery (CGS) affect glaucoma medication usage. We recruited patients who received new diagnoses of glaucoma, either primary open-angle glaucoma (POAG) (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code 365.1) or primary angle-closure glaucoma (PACG) (ICD-9-CM code 365.2), between 1998 and 2011 and had undergone cataract surgery alone (CS), glaucoma surgery alone (GS), or CGS under the National Health Insurance program in Taiwan. CS, GS, and CGS in all the patients were performed after the glaucoma diagnosis date. The patients were subdivided into CS, CGS, and GS groups. The number of glaucoma medications, including prostaglandin analogs, β-blockers, carbonic anhydrase inhibitors, α-agonists, pilocarpine, and a combination of drugs, in each prescription, were compared before and after surgery.

The mean number of glaucoma medications in each prescription before the surgery increased from approximately 0.5/1 (CS/GS + GS) to a peak of 1.75/3 within 3 months before the index date. The mean number of glaucoma medications in each prescription reduced to 0 (CS group) and to approximately 0.5 (CGS and GS) at the end of the 3-year follow-up period. The mean number of glaucoma medications in each prescription significantly reduced at the time points within 6 months, between 6 months and 2 years, and during 2 to 3 years after surgery in each group. At the end of the 3-year period, the reduction effect was most evident in the CS group. Similar trends were also observed in the POAG and PACG group.

CS, GS, and CGS significantly reduced the number of glaucoma medications used by the glaucoma patients.

Abbreviations: CGS = combined cataract and glaucoma surgery, CS = cataract surgery alone, GEE = generalized estimating equations, GS = glaucoma surgery alone, ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification, IOP = Intraocular pressure, NHIRD = National Health Insurance Research Database, PACG = primary angle-closure glaucoma, POAG = primary open-angle glaucoma, RR = relative ratio.

Keywords: cataract, glaucoma medication, glaucoma surgery

1. Introduction
Several studies have shown that cataract extraction plays a crucial role in the controlling intraocular pressure (IOP) in comorbid glaucoma.[1–4] A recent large clinical trial showed that clear lens extraction was more efficacious in IOP control and more cost-effective than laser peripheral iridotomy, and it has been suggested as a first-line treatment for primary angle-closure glaucoma (PACG).[5] However, the role of phacoemulsification in treating primary open-angle glaucoma (POAG) remains controversial.[11] No strong evidence from large randomized

Editor: Xiong Kun.

The NHIRD encrypts personal data of patients to protect their privacy and provides researchers with anonymous identification numbers associated with relevant claims data, including sex, date of birth, medical services received, and prescriptions. Therefore, patient consent is not required before accessing their data from the NHIRD. This study fulfilled the condition for exemption by the Institutional Review Board (IRB) of China Medical University (CMUH104-REC2-115-CR3). Furthermore, the IRB waived the patient consent requirement.

This work was supported by grants from the Ministry of Health and Welfare of Taiwan (MOHW107-TDU-B-212-12304); China Medical University Hospital (CMU106-ASIA-12, DMR-107-192); Academia Sinica Stroke Biosignature Project (BM10701010021); MOST Clinical Trial Consortium for Stroke (MOST 107-2321-B-039 -004-); Tseng-Lien Lin Foundation, Taichung, Taiwan; and Katsuzo and Kiyo Aoshima Memorial Funds, Japan. The funders had no role in the study design, data collection, and analysis, the decision to publish, or preparation of the manuscript. No additional external funding was received for this study.

The authors have no conflicts of interest to disclose.

*College of Medicine, †Department of Ophthalmology, ‡Management Office for Health Data, §Graduate Institute of Biomedical Sciences and School of Medicine, College of Medicine, ¶Department of Nuclear Medicine and PET Center, China Medical University Hospital, ¶Department of Bioinformatics and Medical Engineering, Asia University, Taichung, Taiwan.

*Correspondence: Chia-Hung Kao, Graduate Institute of Biomedical Sciences and School of Medicine, College of Medicine, China Medical University, No. 2, Yuh-Der Road, Taichung 404, Taiwan (e-mails: d10040@mail.cmuh.org.tw, dr.kaochiahung@gmail.com); Hsin-Yi Chen, School of Medicine, Medical College, China Medical University, Taichung, Taiwan. No. 2, Yuh-Der Road, Taichung 404, Taiwan (e-mail: glaucoma0606@gmail.com).

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Medicine (2019) 98(14):e14128
Received: 2 October 2018 / Received in final form: 18 December 2018 / Accepted: 19 December 2018
https://dx.doi.org/10.1097/MD.00000000000014128
trials elucidating the role of phacoemulsification is yet available, and available data have been interpreted inconsistently.[6–11] To enhance our understanding of this crucial problem, we designed a study to determine whether cataract surgery alone (CS) or glaucoma surgery alone (GS) and combined cataract and glaucoma surgery (CGS) affects glaucoma medication usage in Taiwanese patients by using data from the National Health Insurance Research Database (NHIRD). We recruited patients who received new diagnoses of glaucoma (International Classification of Disease, Ninth Revision, Clinical Modification [ICD-9-CM] code 365) between 1998 and 2011 and had undergone either CS, GS, or CGS. To our knowledge, this study is among the few studies worldwide that have investigated this crucial topic by using a large claims database.

2. Patients and methods

2.1. Data source

In Taiwan, the National Health Insurance (NHI) program, launched by the government in 1995, covers all citizens except prison inmates. In this study, patient records were obtained from the NHIRD, which is released and maintained by the National Health Research Institutes. The NHIRD covers approximately 99% of Taiwan’s population and provides registration files and inpatient, outpatient, and pharmacy claims data for all insured individuals (http://www.nhi.gov.tw/english/index.aspx). Longitudinal data of medical history records are linked to an encrypted personal identification number of each patient. The diagnostic codes in the NHIRD follow the format of the ICD-9-CM.

2.2. Data availability statement

The data set used in this study is managed by the Taiwan Ministry of Health and Welfare (MOHW). Approval of our application by the MOHW was required to access this data. Any researcher interested in accessing this dataset can submit an application form to the MOHW requesting access. The staff of MOHW can be contacted at stcarolwu@mohw.gov.tw or No.488, Sec. 6, Zhongxiao E. Rd., Nangang Dist., Taipei City 115, Taiwan (R. O. C.) (Phone: +886-2-8590-6848) for further assistance. All relevant data are presented within the paper.

2.3. Study patients

Patients who received new diagnoses of glaucoma (ICD-9-CM code 365), both POAG (ICD-9-CM code 365.1) and PACG (ICD-9-CM code 365.2), between 1998 and 2011 and underwent CS (phacoemulsification or extracapsular lens extraction), GS (trabeculectomy), or CGS after glaucoma diagnosis were identified. The identified patients were divided into 3 groups: CS, CGS, and GS, but patients aged <20 years were excluded. The study index date was the last date of CS or GS. We compared the number of glaucoma medications, including prostaglandin analogs (PGAs), β-blockers, carbonic anhydrase inhibitors (CAIs), α-agonists, pilocarpine, and a combination of drugs, of each prescription before and after index date among the 3 groups was measured using the sign test. Generalized estimating equations (GEEs) adjusted for age and sex by using Poisson’s distribution and log link were used to compare the relative changes in the number of glaucoma medications in each prescription before surgery (6 months) and after surgery (within 6 months, between 6 months and 2 years, and during 2–3 years). Relative ratio (RRs) and 95% confidence intervals (CIs) obtained from the GEE model indicated the after-to-before (with reference to the index date) average number of glaucoma medications required simultaneously. All P values less than .05 were considered significant.

3. Results

Figure 1 shows the flow chart of patient selection process.

3.1. Demographic data of the patients

The patients in the CS group were older than those in the CGS and GS groups, and 55.7% of the total 4369 patients were women (Table 1). The patients in the GS group were the youngest among the 3 groups, and 64.6% of them (216 patients) were men. Among the groups, the mean number of glaucoma medications in each prescription before the surgery increased from approximately 0.51 (CS/GS + CGS) at 6 months before the index date to 1.75/3 within 3 months before the index date (Fig. 2). The mean number of glaucoma medications of each prescription reduced to 0 (in the CS group) and approximately 0.5 (in the GS and CGS groups) at the end of the 3-year period after the index date.

3.2. Changes in the number of glaucoma medications before and after surgery

The mean numbers of glaucoma medications in each prescription significantly reduced within 6 months, between 6 months and 2 years, and during 2 to 3 years in all the groups (Table 2). At the end of the 3-year period, the reduction effect was most clearly visible in the CS group (RR = 0.19, 95% CI = 0.18–0.20). Significant reductions were also observed in the other 2 groups (RR = 0.31 with 95% CI = 0.27–0.35 and RR = 0.23 with 95% CI = 0.20–0.27 in the CGS and GS groups, respectively). Similar trends were also observed in the POAG or PACG groups.

3.3. Changes in number of glaucoma medication stratified by age and sex

Further analyses stratified by age and sex are presented in Table 3. We stratified the patients in the 3 groups by age and sex to evaluate differences attributable to differences in surgery different age groups and sex groups. We observed significant reductions in all strata among all the groups.

4. Discussion

Our results showed that CS, GS, or CGS significantly reduced glaucoma medication usage in the Taiwanese patients, which indirectly indicated the IOP-lowering effect of these surgical procedures. Moreover, another crucial finding was that the glaucoma patients in the CS group were considerably older than those in the other 2 groups (mean age: 69.0 years). The patients in the GS group were the youngest among the 3 groups (mean age: 56.3 years). To our knowledge, clinicians in clinical practice...
Consider decision making for glaucoma treatment a major challenge. Crucial factors, including the level of IOP, severity of cataract, corneal condition, and optic nerve function, should be considered simultaneously to arrive at the correct decision. For glaucoma patients without cataract, trabeculectomy is clearly the first choice for reducing IOP. Therefore, the mean age of the patients in this group is less than the mean ages of the patients in the other groups. However, for glaucoma patients...
### Table 2

|                           | 6 months before surgery | 6 months after surgery | Change 6 months to 2 years | Change 2-3 year | Change after surgery | 2 years after surgery |
|---------------------------|-------------------------|------------------------|-----------------------------|-----------------|---------------------|----------------------|
|                           | Mean, SD                | Mean, SD               | P value, 95% CI             | Mean, SD        | P value, 95% CI      | Mean, SD             |
| Cataract surgery alone    | 1.22 (1.30)             | 0.29 (0.75)            | -0.92 (1.03)                | <0.001          | 0.32 (0.31, 0.34)    | 0.36 (0.30)          |
| Cataract + glaucoma surgery | 2.63 (1.48)             | 1.21 (1.18)            | -1.62 (1.35)                | <0.001          | 0.43 (0.39, 0.46)    | 1.31 (1.39)          |
| Glaucoma surgery alone    | 3.04 (1.43)             | 1.16 (1.12)            | -1.88 (1.51)                | <0.001          | 0.38 (0.35, 0.42)    | 1.17 (1.28)          |
| POAG                      |                         |                        |                             |                 |                     |                      |
| Cataract surgery alone (N=545) | 1.52 (1.30)             | 0.47 (0.78)            | -0.90 (1.04)                | <0.001          | 0.31 (0.28, 0.30)    | 0.42 (0.38)          |
| Glaucoma surgery alone (N=24) | 3.33 (1.74)             | 1.09 (1.14)            | -1.92 (1.38)                | <0.001          | 0.35 (0.24, 0.50)    | 1.04 (1.16)          |
| PACG                      |                         |                        |                             |                 |                     |                      |
| Cataract surgery alone (N=103) | 1.17 (1.40)             | 0.47 (0.73)            | -1.31 (1.20)                | <0.001          | 0.26 (0.24, 0.29)    | 0.41 (0.39)          |
| Cataract + glaucoma surgery (N=53) | 3.32 (1.57)             | 0.92 (1.34)            | -2.40 (1.56)                | <0.001          | 0.28 (0.20, 0.40)    | 1.30 (1.65)          |
| Glaucoma surgery alone (N=54) | 3.41 (1.31)             | 1.09 (1.14)            | -2.31 (1.63)                | <0.001          | 0.32 (0.24, 0.43)    | 1.02 (1.34)          |

1 Sign test.
2 GEE model adjusted for age, and sex.

### Discussion

A recent meta-analysis of 5 treatment arms revealed that with cataract surgery alone (CS), the reduction in IOP at 1 year was significantly larger in POAG patients (1.30) than in PACG patients (1.17). Interestingly, the reduction in IOP in PACG patients was significantly larger in the CS group (1.43) than in the POAG group (1.17). The authors suggested that this difference might be due to the higher rate of concurrent glaucoma medications in PACG patients. Moreover, the reduction in IOP was significantly larger in POAG patients than in PACG patients in the CS group (1.43) compared to the POAG group (1.17). In the PACG group, the reduction in IOP was less significant (1.17) compared to the POAG group (1.43).

### Conclusion

The results of this study suggest that cataract surgery alone (CS) and cataract + glaucoma surgery (CS+GD) are effective in reducing IOP and glaucoma medications in patients with POAG and PACG. However, the reduction in IOP and glaucoma medications was more pronounced in POAG patients treated with CS compared to PACG patients. Further studies are needed to confirm these findings and to explore the role of concurrent glaucoma medications in the IOP reduction and glaucoma control after cataract surgery.
### Table 3

Changes in the number of glaucoma medication stratified by age and sex.

|                          | 6 months before surgery | 6 months after surgery | Change | 6 months to 2 years after surgery | Change | 2–3 years after surgery | Change |
|--------------------------|-------------------------|------------------------|--------|-----------------------------------|--------|-------------------------|--------|
|                          | Mean, SD                | Mean, SD               | P value | Relative Ratio, 95% CI            | Mean, SD | Mean, SD               | P value | Relative ratio, 95% CI |
| **Cataract surgery alone** |                         |                        |         |                                   |         |                         |         |
| **Age, years**           |                         |                        |         |                                   |         |                         |         |
| ≤49                      | 1.44 (1.38)             | 0.55 (0.92)            | <.001   | 0.38 (0.33, 0.43)                 | 0.54 (1.04) | −0.91 (1.22)            | <.001   | 0.37 (0.32, 0.44)     | 0.27 (0.70) | −1.18 (1.32) | <.001 | 0.19 (0.14, 0.24) |
| 50–64                    | 1.26 (1.29)             | 0.40 (0.77)            | <.001   | 0.32 (0.30, 0.34)                 | 0.37 (0.83) | −0.88 (1.21)            | <.001   | 0.30 (0.27, 0.33)     | 0.25 (0.66) | −1.01 (1.26) | <.001 | 0.20 (0.18, 0.22) |
| 65+                      | 1.19 (1.29)             | 0.38 (0.73)            | <.001   | 0.32 (0.31, 0.34)                 | 0.34 (0.76) | −0.84 (1.19)            | <.001   | 0.29 (0.28, 0.30)     | 0.22 (0.62) | −0.97 (1.22) | <.001 | 0.18 (0.17, 0.20) |
| **Sex**                  |                         |                        |         |                                   |         |                         |         |
| Female                   | 1.18 (1.28)             | 0.37 (0.73)            | <.001   | 0.31 (0.30, 0.33)                 | 0.33 (0.76) | −0.84 (1.14)            | <.001   | 0.28 (0.27, 0.30)     | 0.21 (0.59) | −0.97 (1.20) | <.001 | 0.18 (0.17, 0.19) |
| Male                     | 1.26 (1.31)             | 0.43 (0.77)            | <.001   | 0.34 (0.32, 0.35)                 | 0.40 (0.84) | −0.87 (1.20)            | <.001   | 0.31 (0.29, 0.33)     | 0.25 (0.68) | −1.02 (1.28) | <.001 | 0.20 (0.18, 0.21) |
| **Cataract and glaucoma surgery alone** |                     |                        |         |                                   |         |                         |         |
| **Age, years**           |                         |                        |         |                                   |         |                         |         |
| ≤49                      | 3.06 (1.48)             | 1.56 (1.31)            | <.001   | 0.51 (0.35, 0.74)                 | 1.31 (1.35) | −1.75 (2.08)            | .01     | 0.43 (0.25, 0.75)     | 1.00 (1.10) | −2.06 (1.88) | <.003 | 0.33 (0.18, 0.58) |
| 50–64                    | 2.77 (1.45)             | 1.11 (1.11)            | <.001   | 0.40 (0.34, 0.47)                 | 1.20 (1.31) | −1.57 (1.63)            | <.001   | 0.43 (0.36, 0.53)     | 0.89 (1.26) | −1.88 (1.63) | <.001 | 0.32 (0.25, 0.41) |
| 65+                      | 2.84 (1.49)             | 1.23 (1.19)            | <.001   | 0.43 (0.39, 0.47)                 | 1.35 (1.36) | −1.49 (1.50)            | <.001   | 0.47 (0.43, 0.53)     | 0.85 (1.09) | −1.99 (1.67) | <.001 | 0.30 (0.26, 0.35) |
| **Sex**                  |                         |                        |         |                                   |         |                         |         |
| Female                   | 2.78 (1.50)             | 1.13 (1.16)            | <.001   | 0.41 (0.36, 0.46)                 | 1.24 (1.42) | −1.53 (1.59)            | <.001   | 0.45 (0.39, 0.52)     | 0.83 (1.17) | −1.95 (1.69) | <.001 | 0.30 (0.25, 0.36) |
| Male                     | 2.87 (1.46)             | 1.27 (1.19)            | <.001   | 0.44 (0.40, 0.49)                 | 1.36 (1.28) | −1.51 (1.53)            | <.001   | 0.47 (0.42, 0.53)     | 0.89 (1.11) | −1.98 (1.65) | <.001 | 0.31 (0.27, 0.37) |
| **Glaucoma surgery alone** |                         |                        |         |                                   |         |                         |         |
| **Age, years**           |                         |                        |         |                                   |         |                         |         |
| ≤49                      | 3.31 (1.46)             | 1.31 (1.25)            | <.001   | 0.40 (0.34, 0.47)                 | 1.32 (1.38) | −1.99 (1.60)            | <.001   | 0.40 (0.33, 0.48)     | 0.82 (1.09) | −2.49 (1.67) | <.001 | 0.25 (0.19, 0.32) |
| 50–64                    | 2.78 (1.44)             | 1.05 (0.99)            | <.001   | 0.38 (0.31, 0.45)                 | 1.05 (1.14) | −1.73 (1.60)            | <.001   | 0.38 (0.31, 0.46)     | 0.61 (0.94) | −2.17 (1.78) | <.001 | 0.22 (0.16, 0.30) |
| 65+                      | 3.01 (1.37)             | 1.12 (1.11)            | <.001   | 0.37 (0.31, 0.44)                 | 1.12 (1.20) | −1.89 (1.71)            | <.001   | 0.37 (0.30, 0.46)     | 0.68 (1.11) | −2.32 (1.72) | <.001 | 0.23 (0.17, 0.31) |
| **Sex**                  |                         |                        |         |                                   |         |                         |         |
| Female                   | 2.87 (1.46)             | 1.17 (1.16)            | <.001   | 0.36 (0.31, 0.43)                 | 1.14 (1.34) | −2.08 (1.72)            | <.001   | 0.35 (0.29, 0.44)     | 0.73 (1.16) | −2.49 (1.81) | <.001 | 0.23 (0.17, 0.30) |
| Male                     | 2.94 (1.41)             | 1.16 (1.11)            | <.001   | 0.39 (0.35, 0.45)                 | 1.18 (1.25) | −1.76 (1.59)            | <.001   | 0.40 (0.35, 0.46)     | 0.69 (0.99) | −2.24 (1.67) | <.001 | 0.24 (0.19, 0.29) |

*Sign test.
†GEE model adjusted for age, and sex.
clinical information regarding IOP level, anterior chamber depth, visual acuity, visual field findings, and optic nerve evaluations are not available. To improve patient selection accuracy, we selected patients with both diagnostic and surgery codes. Furthermore, in actual clinical practice, the optimal timing for decision making for selection of the surgical procedure for each glaucoma patient is 6 months before surgery. Therefore, we evaluated the medication usage 6 months before surgery. We did not recruit patients based on medication usage coding because not all glaucoma patients used glaucoma medications 6 months before surgery. Second, laboratory and imaging data were not available in the individual chart records. The NHIRD is used primarily for insurance purposes and has not been validated entirely for research; thus, uncontrolled confounding factors such as visual field severity, IOP readings, and potential biases may have affected our retrospective case-control study. Third, despite the large sample size, the study cohort consisted of Taiwanese patients; hence, these findings are not adequately applicable to other populations. Fourth, patients with glaucoma received CS, GS or CGS, depending on the decisions of their doctors; therefore, the result might not be representative of the entire population. Future prospective longitudinal study, including other outcomes such as quality of life, clinical severity information, and cost-effectiveness analysis, are required to provide evidence to support treatment recommendations.

Our study had the following strengths. First, the strength of the database is excellent because of the large sample randomization. Moreover, we could follow-up the patients over time to assess glaucoma medication usage before and after these surgical procedures.[17] Second, the database includes data on a broad range of people with different sociodemographic profiles, unlike some smaller studies in which patients are recruited from specific regions. The study populations selected in these studies might not be representative of the entire population.[17] Third, our study is the first to evaluate glaucoma medication usage before and after CGS, CS, or GS in a purely Chinese population using by a large claims database. Our findings can provide a strong foundation for further longitudinal research.

In conclusion, CGS, CS, and GS significantly reduced the number of glaucoma medication used by the glaucoma patients. A similar trend was observed in the POAG and PACG groups.

Author contributions
Design and conduct: Hsin-Yi Chen, Cheng-Li Lin, Chia-Hung Kao
Analyze the data: Hsin-Yi Chen, Cheng-Li Lin, Chia-Hung Kao
Write the manuscript: Hsin-Yi Chen, Cheng-Li Lin, Chia-Hung Kao
Modify the manuscript: Hsin-Yi Chen, Chia-Hung Kao
Final approval of manuscript: Hsin-Yi Chen, Cheng-Li Lin, Chia-Hung Kao
Conceptualization: Hsin-Yi Chen.
Data curation: Hsin-Yi Chen, Cheng-Li Lin, Chia-Hung Kao.
Formal analysis: Cheng-Li Lin.
Funding acquisition: Chia-Hung Kao.
Investigation: Chia-Hung Kao.
Methodology: Hsin-Yi Chen, Cheng-Li Lin.
Project administration: Chia-Hung Kao.
Resources: Chia-Hung Kao.
Software: Cheng-Li Lin.
Supervision: Chia-Hung Kao.
Validation: Hsin-Yi Chen, Cheng-Li Lin.
Writing – original draft: Hsin-Yi Chen, Cheng-Li Lin.
Writing – review & editing: Hsin-Yi Chen, Chia-Hung Kao.

References
[1] Masis M, Mineault PJ, Phan E, et al. The role of phacoemulsification in glaucoma therapy: a systematic review and meta-analysis. Surv Ophthalmol 2018;63:700–10.
[2] Hsia YC, Moghimi S, Coh P, et al. Anterior segment parameters as predictors of intraocular pressure reduction after phacoemulsification in eyes with open-angle glaucoma. J Cataract Refract Surg 2017;43:879–85.
[3] Armstrong JJ, Wasuuta T, Kiatos E, et al. The effects of phacoemulsification on intraocular pressure and topical medication use in patients with glaucoma: a systematic review and meta-analysis of 3-year data. J Glaucoma 2017;26:511–22.
[4] Chen PP, Lin SG, Junk AK, et al. The effect of phacoemulsification on intraocular pressure in glaucoma patients: a report by the American academy of ophthalmology. Ophthalmology 2015;122:1294–307.
[5] Azuara-Blanco A, Burr J, Ramsay C, et al. EAGLE study group. Effectiveness of early lens extraction for the treatment of primary angle-closure glaucoma (EAGLE): a randomised controlled trial. Lancet 2016;388:1389–97.
[6] Thomas R, Walland M, Thomas A, et al. Lowering of intraocular pressure after phacoemulsification in primary open-angle and angle-closure glaucoma: a bayesian analysis. Asia Pac J Ophthalmol (Phila) 2016;5:79–84.
[7] Walland MJ, Parikh RS, Thomas R. There is insufficient evidence to recommend lens extraction as a treatment for primary open-angle glaucoma: an evidence-based perspective. Clin Exp Ophthalmol 2012;40:400–7.
[8] Shrivastava A, Singh K. The effect of cataract extraction on intraocular pressure. Curr Opin Ophthalmol 2010;21:118–22.
[9] Vizzioli G, Weinreb RN. Cataract surgery and glaucoma. Curr Opin Ophthalmol 2010;21:20–4.
[10] Brown RH, Zhong L, Lynch MG. Lens-based glaucoma surgery: using cataract surgery to reduce intraocular pressure. J Cataract Refract Surg 2014;40:1255–62.
[11] Walland MJ, Thomas R. Lens surgery to treat open-angle glaucoma: triumph of hope over (evidence-based) experience. J Cataract Refract Surg 2015;41:247–8.
[12] Zhang ML, Hirunyachote P, Jampel H. Combined surgery versus cataract surgery alone for eyes with cataract and glaucoma. Cochrane Database Syst Rev 2015;14:CD008671.
[13] Azuara-Blanco A, Burr JM, Cochran C, et al. The effectiveness of early lens extraction with intraocular lens implantation for the treatment of primary angle-closure glaucoma (EAGLE): study protocol for a randomized controlled trial. Trials 2011;12:133.
[14] Javanbakht M, Azuara-Blanco A, Burr JM, et al. Early lens extraction with intraocular lens implantation for the treatment of primary angle closure glaucoma (EAGLE): a bayesian analysis. Asia Pac J Ophthalmol (Phila) 2017;6:222.
[15] Chang FY, Wang JY, Chang SW, et al. Changes in ocular hypertensive drug usage for glaucoma treatment after cataract surgery: a nationwide population-based study in Taiwan. J Glaucoma 2018;27:600–5.
[16] Su CW, Chang YC, Lin CL. Association of neovascular glaucoma with risk of stroke: a population-based cohort study. J Ophthalmol 2017;2017:1851568.
[17] Chen HY, Lin CL, Kao CH. Does migraine increase the risk of glaucoma?: a population-based cohort study. Medicine (Baltimore) 2016;95:e3670.